The Indian pharmaceutical industry commands a significant share of more than 20 percent in the global medical supply chain. With the interim budget coming up, the Indian pharma industry is expecting tax breaks, benefits that are focussed on research and development (R&D) and a further boost in the production linked incentive (PLI) Scheme.